Sensei price target raised to $35 at Stephens to reflect 1-for-20 reverse split

Stephens raised the firm’s price target on Sensei Biotherapeutics (SNSE) to $35 from $4 and keeps an Overweight rating on the shares. The price target increase reflects the recent 1-for-20 reverse stock split that went into effect on June 17, the analyst tells investors in a research note.